Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics (Nasdaq: KPTI) granted inducement awards to seven newly hired employees as of November 30, 2025 under its 2022 Inducement Stock Incentive Plan.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted inducement awards to seven newly hired employees as of November 30, 2025 under its 2022 Inducement Stock Incentive Plan.

The company issued stock options to purchase an aggregate of 2,800 shares at an exercise price of $5.62 (closing price on the Grant Date) and granted an aggregate of 15,791 restricted stock units (RSUs). Options vest over four years (25% after one year, then monthly 1/48th), and RSUs vest over three years (33 1/3% each year), each subject to continued service.

Argus Dec 2 session

-6.78% close to close Open Argus

Details

News Market Reaction – KPTI

On Dec 2, the first trading day after this news, KPTI closed 6.78% below the previous close.

Data tracked by StockTitan Argus for the Dec 2 session.

Market Context

On Dec 2, the first trading day after this news, the stock closed 6.8% below the previous close. A n...

Analysis

On Dec 2, the first trading day after this news, the stock closed 6.8% below the previous close. A negative reaction despite routine inducement grants would fit a pattern where stock moves have sometimes diverged from neutral news, as seen around prior inducement announcements. The shares were trading above the 200-day moving average with volume running at 4.28x the 20-day average before this filing, so position‑cleaning or sensitivity to equity-related headlines could have amplified pressure. Existing resale registrations covering 2,805,688 shares by selling stockholders may also remain in focus.

Key Figures

Stock options granted: 2,800 shares RSUs granted: 15,791 RSUs Option exercise price: $5.62 per share +5 more

Stock options granted

2,800 shares

Inducement stock option grants as of Nov 30, 2025

RSUs granted

15,791 RSUs

Inducement awards to seven newly hired employees

Option exercise price

$5.62 per share

Closing price on the Nov 30, 2025 Grant Date

Option vesting period

4 years

25% after one year, then 1/48th monthly

Initial cliff vest

25%

Portion of options vesting on one-year anniversary

Monthly vesting rate

1/48th of options

Monthly vesting after first anniversary

RSU vesting period

3 years

Inducement RSUs vesting annually

Annual RSU vesting tranche

33 1/3%

Portion of RSUs vesting on each Grant Date anniversary

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   Conference participation

   24h Move

   +2.4%

   Announcement of virtual fireside chat in Baird’s Biotech Discovery Series.

2. Dec 01

   Inducement grants

   24h Move

   -6.8%

   Disclosure of stock options and RSUs granted to seven new employees.

3. Dec 01

   Conference participation

   24h Move

   +2.3%

   Planned fireside chat at Piper Sandler healthcare conference in New York.

4. Nov 03

   Inducement grant

   24h Move

   +4.7%

   Grant of 800 RSUs to a new hire under inducement plan.

5. Nov 03

   Earnings update

   24h Move

   +4.7%

   Q3 2025 results with net loss and going‑concern discussion alongside guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), stock option, restricted stock units (rsus), exercise price, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock option financial

"granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

restricted stock units (rsus) financial

"an aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

exercise price financial

"The stock options have an exercise price of $5.62 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vest over four years, with 25% of the total number of shares underlying the stock options vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an  aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees. These awards were granted as of November 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $5.62 per share, the closing price of Karyopharm's common stock on the Grant Date and vest over four years, with 25% of the total number of shares underlying the stock options vesting on the one-year anniversary of the employee's commencement date and 1/48th of the total number of shares vesting monthly thereafter, subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. 

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302629473.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Karyopharm (KPTI) grant on November 30, 2025?

Karyopharm granted options for an aggregate of 2,800 shares and 15,791 RSUs to seven newly hired employees, effective November 30, 2025.

What is the exercise price of the KPTI stock options granted as inducements?

The exercise price is $5.62 per share, equal to Karyopharm's closing price on the Grant Date.

How do the KPTI stock options vest for the November 30, 2025 grants?

Options vest over four years: 25% after one year, then 1/48th monthly thereafter, subject to continued service.

What is the vesting schedule for the RSUs KPTI awarded to new hires?

Each RSU award vests over three years with 33 1/3% vesting each year, subject to continued service.

Why were the inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as inducements material to new employees entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4).